Stockholm, 31 August 2018 – Nuevolution AB (publ) (NUE.ST) today announced the appointment of Mr. Johnny Stilou as Chief Financial Officer (CFO) with immediate effect. Johnny Stilou will take over the position as CFO after Mr. Henrik Simonsen, who will be leaving Nuevolution to pursue other opportunities.

Johnny Stilou, 51 years, joined Nuevolution in February 2018 in the position as Director of Investor Relations & Corporate Communication. He has a background as M.Sc. in Business Economics & Auditing from Copenhagen Business School and has completed the Executive Management Program at INSEAD. Johnny began his career as an Auditor with KPMG, following which he held several international Finance positions at GN Store Nord. Most recently he was CFO at Fritz Schur Technical Group, and prior to this during the eight years from 2008 to 2016, he was CFO at the Nasdaq Copenhagen public listed Veloxis Pharmaceuticals (midcap).

Johnny is a seasoned CFO with experience from several listed companies and has brought significant experience including international experience to Nuevolution. In the past he has secured multiple financing rounds, including providing key financing for human clinical trials, and he has experience from regulatory approval processes and product market launches. During his first 6 months at Nuevolution, Johnny has been significantly involved in the company’s financial reporting internally and externally, interactions with auditors, raise of capital and investor relation activities.

Johnny Stilou will remain responsible for Nuevolution’s investor relations and corporate communication. With the organizational change, the company will consider the opportunity to strengthen these areas further.

“I am very pleased to be able to transfer the important responsibility as CFO to Johnny Stilou. Johnny is already well acquainted with all on-going activities, and with Johnny’s background and experience, Nuevolution has a very experienced CFO”, said Alex Gouliaev, Chief Executive Officer of Nuevolution, and continued “I would also like to thank Henrik Simonsen for his support to the company during the last three years, and I wish Henrik all the best with his future activities”.

For more information, please contact:
Alex Gouliaev, CEO
Tel.: +45 2725 1402

Information about Nuevolution AB (publ)
Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and develops its programs alone and in collaboration with pharmaceutical and biotechnology companies to seek future benefit for patients in need of novel medical treatment options. Nuevolution’s internal programs are focused on therapeutically important diseases targets within severe inflammatory diseases and cancer.

This information is information that Nuevolution AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact persons set out above, on Friday 31 August 2018 at 16.15 CET.

Nuevolution AB (publ) is listed at Nasdaq in Stockholm, Sweden (ticker: NUE). More information about Nuevolution can be found on: